Conclusion
Patients with CF who have received a liver transplant may be initiated
on elx/tez/iva with demonstrated safety and clinical efficacy. Frequent
LFT monitoring is warranted and can be used to guide elx/tez/iva dose
titrations. Early and close therapeutic drug monitoring of
immunosuppression is important to ensure safety and efficacy of the
regimen. Additional research is necessary to determine long term safety
and efficacy of elx/tez/iva in patients with CF status-post liver
transplantation.